Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study
Jennifer R. Bellon, Filipa C. Lynce, R. Shi, Meredith M. Regan et al.
Journal
Breast Cancer Research
Topics
Breast Cancer Treatment Studies
article
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study
Jennifer R. Bellon, Filipa C. Lynce, R. Shi, Meredith M. Regan, Faina Nakhlis, Beth Harrison, Molly K. DiLullo, Lei Qin, Laura Warren, McKenna Moore, Kristina A. Fanucci, Camden Bay, Ashka Patel, Sara M. Tolaney, Steven Van Laere, Zachary T. Herbert, Beth Overmoyer, Eren D. Yeh, Jennifer L. Guerriero
article en
Abstract
No abstract available for this paper.
Publication Tag
Breast Cancer ResearchVol. 27(1)
Institutions
Brigham and Women's Hospital (US), Harvard University (US), University of Antwerp (BE), Dana-Farber Cancer Institute (US), Takeda (United States) (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study — Jennifer R. Bellon, Filipa C. Lynce, et al. · Breast Cancer Research (2025) | TGRS Research Map | TGRS